Literature DB >> 16493152

Chronic obstructive pulmonary disease: from unjustified nihilism to evidence-based optimism.

Bartolome R Celli1.   

Abstract

Chronic obstructive pulmonary disease (COPD) has been associated with a nihilistic attitude. On the basis of current evidence, this nihilistic attitude is totally unjustified. The disease must be viewed through the lens of a new paradigm: one that accepts COPD as not only a pulmonary disease but also as one with important measurable systemic consequences. COPD is not only preventable but also treatable. Smoking cessation, oxygen for hypoxemic patients, lung reduction surgery for selected patients with emphysema, and noninvasive ventilation during severe exacerbations have all been shown to impact on mortality. In addition, pulmonary rehabilitation, pharmacologic therapy, and lung transplantation improve patient-centered outcomes such as health-related quality of life, dyspnea, exercise capacity, and even exacerbations and hospitalizations. Caregivers should familiarize themselves with the multiple complementary forms of treatment and individualize therapy to the particular situation of each patient. The future for patients with this disease is bright as its pathogenesis and clinical and phenotypic manifestations are unraveled. The advent of newer and more effective therapies will lead to a decline in the contribution of this disease to poor world health.

Entities:  

Mesh:

Year:  2006        PMID: 16493152     DOI: 10.1513/pats.200510-111JH

Source DB:  PubMed          Journal:  Proc Am Thorac Soc        ISSN: 1546-3222


  11 in total

1.  Can early diagnosis and effective management combat the irresistible rise of COPD?

Authors:  Rupert Jones
Journal:  Br J Gen Pract       Date:  2006-09       Impact factor: 5.386

2.  Chronic obstructive pulmonary disease: a view from the NHLBI.

Authors:  Antonello Punturieri; Thomas L Croxton; Gail G Weinmann; James P Kiley
Journal:  Am J Respir Crit Care Med       Date:  2008-09-01       Impact factor: 21.405

3.  Primary Care Physicians', Nurse Practitioners' and Physician Assistants' Knowledge, Attitudes and Beliefs Regarding COPD: 2007 To 2014.

Authors:  Barbara P Yawn; Peter C Wollan; Kyle B Textor; Roy A Yawn
Journal:  Chronic Obstr Pulm Dis       Date:  2016-05-06

4.  Development of the Lung Function Questionnaire (LFQ) to identify airflow obstruction.

Authors:  Barbara P Yawn; Douglas W Mapel; David M Mannino; Fernando J Martinez; James F Donohue; Nicola A Hanania; Mark Kosinski; Regina Rendas-Baum; Matthew Mintz; Steven Samuels; Anand A Dalal
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2010-02-18

5.  Lung cancer and chronic obstructive pulmonary disease: needs and opportunities for integrated research.

Authors:  Antonello Punturieri; Eva Szabo; Thomas L Croxton; Steven D Shapiro; Steven M Dubinett
Journal:  J Natl Cancer Inst       Date:  2009-04-07       Impact factor: 13.506

Review 6.  Molecular pathogenesis of emphysema.

Authors:  Laimute Taraseviciene-Stewart; Norbert F Voelkel
Journal:  J Clin Invest       Date:  2008-02       Impact factor: 14.808

7.  Diagnosing and treating COPD: understanding the challenges and finding solutions.

Authors:  Len Fromer
Journal:  Int J Gen Med       Date:  2011-10-28

8.  Severity of COPD at initial spirometry-confirmed diagnosis: data from medical charts and administrative claims.

Authors:  Douglas W Mapel; Anand A Dalal; Christopher M Blanchette; Hans Petersen; Gary T Ferguson
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2011-11-09

Review 9.  New clinical insights into chronic obstructive pulmonary disease and their implications for pharmacoeconomic analyses.

Authors:  Douglas W Mapel; Melissa H Roberts
Journal:  Pharmacoeconomics       Date:  2012-10-01       Impact factor: 4.981

10.  Warm homes for older people: aims and methods of a randomised community-based trial for people with COPD.

Authors:  Helen Viggers; Philippa Howden-Chapman; Tristram Ingham; Ralph Chapman; Gina Pene; Cheryl Davies; Ann Currie; Nevil Pierse; Helen Wilson; Jane Zhang; Michael Baker; Julian Crane
Journal:  BMC Public Health       Date:  2013-02-26       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.